Tuberculosis Diagnostics Market To Reach $3.18 Billion By 2030

Tuberculosis Diagnostics Market Growth & Trends

The global tuberculosis diagnostics market size is expected to reach USD 3.18 billion by 2030, registering a CAGR of 5.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.

These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.

 Request a free sample copy or view report summary: Tuberculosis Diagnostics Market Report

Tuberculosis Diagnostics Market Report Highlights

• The latent infection detection segment (Skin Test & IGRA) led the market in 2024 with a 40.59% share, driven by the increasing prevalence of tuberculosis.

• Drug Resistance (DST) is projected to achieve the fastest CAGR during the forecast period. DST evaluates the susceptibility of Mycobacterium tuberculosis to various antibiotics, identifying which drugs are effective for treatment.

• In 2024, the diagnostic laboratories segment dominated the TB diagnostics market with the largest revenue share, driven by initiatives to enhance patient outcomes through accessible, retail-level diagnostic services.

• The hospitals and clinics segment is poised for significant growth, driven by increasing TB testing rates in healthcare settings.

• The tuberculosis diagnostics market in Asia Pacific dominated the market with revenue share of 37.18% in 2024 and is expected to witness the fastest growth over the forecast period.

Tuberculosis Diagnostics Market Segmentation

Grand View Research has segmented global tuberculosis diagnostics market report based on type, end-use, and region:

Tuberculosis Diagnostics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Detection of Latent Infection (Skin Test & IGRA)

• Phage Assay

• Detection of Drug Resistance (DST)

• Nucleic Acid Testing

• Radiographic Method

• Cytokine Detection Assay

• Others

Tuberculosis Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Diagnostic Laboratories

• Hospitals & Clinics

• Others

Tuberculosis Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Tuberculosis Diagnostics Market

• Abbott

• QIAGEN

• Thermo Fisher Scientific Inc.

• BD

• F. Hoffmann-La Roche AG

• Hologic, Inc.

• Cepheid

• DiaSorin S.p.A.

• Hain Lifescience GmbH

• Oxford Immunotec